Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 exchanges : Amex save search
Annovis Bio Announces Positive FDA Notice For Buntanetap Phase 3 Clinical Trial In Parkinson's Disease
Published: 2022-07-07 (Crawled : 12:00) - prnewswire.com
ANVS | $12.43 4.63% 43K
|
Health Technology
|
| O: 11.24%
H: 7.12%
C: 1.69%
fda disease trial positive buntanetap anvs401 posiphen phase 3
Timber Pharmaceuticals Announces First Patients Enrolled in Phase 3 ASCEND Clinical Trial Evaluating TMB-001 in Congenital Ichthyosis
Published: 2022-06-23 (Crawled : 14:00) - biospace.com/
TMBR | $0.3426 -2.69% 3K
|
Health Technology
|
| O: 0.7%
H: 1.66%
C: -2.72%
tmb-001 trial phase 3
CEL-SCI Presents Phase 3 Multikine Head & Neck Cancer Data at ASCO
Published: 2022-06-07 (Crawled : 13:00) - biospace.com/
CVM | $1.462 -0.54% 7.5K
|
Health Technology
|
| O: -11.26%
H: 14.2%
C: 12.39%
asco cancer phase 3
Actinium Pharmaceuticals, Inc. Announces 82% of Control Arm Patients Did Not Receive a Bone Marrow Transplant by Conventional Means but 100% of Patients who Received Iomab-B, Including Crossover Patients, in the Phase 3 SIERRA Trial Successfully Engrafted at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR
Published: 2022-04-25 (Crawled : 12:00) - prnewswire.com
ATNM | $7.11 2.16% 39K
|
Health Technology
|
| O: 3.65%
H: 3.23%
C: 2.06%
cibmtr bone control trial therapy phase 3
Actinium Pharmaceuticals, Inc. to Highlight Iomab-B Pivotal Phase 3 SIERRA Trial Data at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR
Published: 2022-04-19 (Crawled : 12:00) - biospace.com/
ATNM | $7.11 2.16% 39K
|
Health Technology
|
| O: 0.9%
H: 11.33%
C: 5.07%
trial therapy phase 3
Red Pine Provides 2022 Phase 1 Exploration Program Update
Published: 2022-03-08 (Crawled : 12:00) - globenewswire.com
PZG | $0.4409 -0.34% 5.6K
|
Non-Energy Minerals
|
| O: 21.58%
H: 6.8%
C: -15.68%
program phase 1 phase 2 phase 3
Ampio Pharmaceuticals, Inc. Releases Positive Phase 3 Data Analysis for Ampion™ Targeting Severe Osteoarthritis of the Knee (OAK)
Published: 2022-03-02 (Crawled : 22:00) - ampiopharma.com
AMPE | $0.286 8K
|
Health Technology
|
| O: 10.43%
H: 2.34%
C: 0.25%
als osteoarthritis positive phase 3
Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease
Published: 2022-01-25 (Crawled : 17:00) - biospace.com/
ANVS | $12.43 4.63% 43K
|
Health Technology
|
| O: 2.75%
H: 5.63%
C: -1.27%
fda parkinson disease positive phase 3 buntanetap
Red Pine Updates on its 2022 Phase 1 Drill Program
Published: 2022-01-05 (Crawled : 12:30) - globenewswire.com
PZG | $0.4409 -0.34% 5.6K
|
Non-Energy Minerals
|
| O: 1.45%
H: 8.26%
C: -1.75%
phase 1 phase 2 phase 3 program
Palatin Announces Initiation of Pivotal Phase 3 PL9643 MELODY-1 Clinical Trial in Patients with Dry Eye Disease
Published: 2021-12-28 (Crawled : 15:30) - biospace.com/
PTN | $1.77 1.14% 13K
|
Health Technology
|
| O: -0.79%
H: 6.4%
C: 3.44%
pl9643 dry eye eye eye disease trial disease phase 3
Actinium Pharmaceuticals, Inc. Announces Pivotal Phase 3 SIERRA Trial at the 63rd ASH Annual Meeting
Published: 2021-12-13 (Crawled : 14:00) - biospace.com/
ATNM | $7.11 2.16% 39K
|
Health Technology
|
| O: 4.48%
H: 0.0%
C: 0.0%
als trial phase 3
Matinas BioPharma Initiates Dosing in Phase 1 Study of Potential First Oral Aminoglycoside Antibiotic Drug MAT2501
Published: 2021-10-21 (Crawled : 13:00) - biospace.com/
MTNB | $0.1823 0.44% 33K
|
Health Technology
|
| O: 0.0%
H: 4.39%
C: 2.63%
biopharma phase 1 potential drug iot phase 2 phase 3
Actinium Completes Enrollment in the Pivotal Phase 3 SIERRA Trial of Iomab-B
Published: 2021-09-15 (Crawled : 12:00) - biospace.com/
ATNM | $7.11 2.16% 39K
|
Health Technology
|
| O: 6.94%
H: 13.31%
C: 10.88%
phase 3 trial enroll
IGC Completes its Phase 1 Clinical Trial on Alzheimer’s Patients, Reports Safety and Tolerability
Published: 2021-09-08 (Crawled : 14:00) - igcinc.us
IGC 4 | $0.45 -1.44% 73K
|
Health Technology
|
| O: 6.92%
H: 1.76%
C: -7.06%
alzheimer phase 1 trial phase 2 phase 3 alzheimer’s alzheimer's
CEL-SCI to Conduct Investor Call Regarding Phase 3 Results Following Annual Shareholder Meeting on July 1, 2021
Published: 2021-06-30 (Crawled : 14:00) - biospace.com/
CVM | $1.462 -0.54% 7.5K
|
Health Technology
|
| O: -6.47%
H: 1.25%
C: -27.67%
results phase 3 cel
CEL-SCI’s Multikine® Immunotherapy Produces Significant 14.1% 5-Year Survival Benefit (62.7% Vs 48.6%) in the Group Receiving Surgery Plus Radiotherapy in a Landmark Head and Neck Cancer Phase 3 Study
Published: 2021-06-28 (Crawled : 16:00) - biospace.com/
CVM | $1.462 -0.54% 7.5K
|
Health Technology
|
| O: 7.26%
H: 1.41%
C: -49.11%
immunotherapy therapy cancer phase 3 iot cel
IGC Completes the Final Cohort of its Phase 1 Clinical Trial on Alzheimer’s Patients
Published: 2021-06-24 (Crawled : 01:00) - igcinc.us
IGC 4 | $0.45 -1.44% 73K
|
Health Technology
|
| O: 17.57%
H: 9.2%
C: -5.17%
alzheimer phase 1 trial phase 2 phase 3 alzheimer’s alzheimer's
IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients
Published: 2021-06-09 (Crawled : 18:00) - igcinc.us
IGC 4 | $0.45 -1.44% 73K
|
Health Technology
|
| O: 0.64%
H: 1.9%
C: -5.7%
alzheimer phase 1 trial phase 3 phase 2 alzheimer’s alzheimer's
Actinium Announces Several Presentations from the Phase 3 SIERRA Study of Iomab-B at the SNMMI 2021 Virtual Annual Meeting
Published: 2021-06-03 (Crawled : 14:00) - biospace.com/
ATNM | $7.11 2.16% 39K
|
Health Technology
|
| O: 0.0%
H: 5.43%
C: 4.81%
presentation phase 3
Galiano Gold Provides Miradani North Phase 3 Drilling Update
Published: 2021-05-20 (Crawled : 12:00) - prnewswire.com
GFI | News | $16.785 -0.62% 510K
|
Non-Energy Minerals
|
| O: 1.77%
H: 2.32%
C: 0.66%
GAU | $1.47 190K
|
Non-Energy Minerals
|
| O: 0.0%
H: 2.8%
C: 0.78%
phase 3
Gainers vs Losers
| 66% | 34% |
Top 10 Gainers
CZOO | $11.44 129.26% 4.6M
|
AMST | $3.4 70.0% 51M
|
Technology Services
BOF | $1.78 52.14% 15M
|
SYRA | $1.5 51.23% 1M
|
n/a
CSSE 4 | $0.23 51.02% 46M
|
Consumer Services
RILY | $30.325 39.62% 6.8M
|
Finance
LICN | $0.76 35.71% 6.2M
|
TROO | $1.41 29.36% 280K
|
Manufacturing
MULN | News | $3.445 26.19% 980K
|
Information
RBBN 4 | $3.21 24.9% 580K
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.